A Phase 2, Single Center, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Cross Over Study to Evaluate the Effects of Multiple Oral Doses of AEF0117 on the Subjective Effects of Cannabis and Cannabis Self-Administration in Subjects With CUD
Latest Information Update: 22 Jun 2020
At a glance
- Drugs AEF 0117 (Primary)
- Indications Substance-related disorders
- Focus Therapeutic Use
- Sponsors Aelis Farma
- 17 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 10 May 2019 Status changed from suspended to recruiting.
- 13 Feb 2019 Planned End Date changed from 1 Sep 2019 to 1 Jul 2020.